Skip to main content
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. — Investor Relations & Filings

Ticker · ELTX ISIN · US03476J1079 US Professional, scientific and technical activities
Filings indexed 348 across all filing types
Latest filing 2025-05-13 Interim / Quarterly Rep…
Country US United States of America
Listing US ELTX

About Elicio Therapeutics, Inc.

https://elicio.com/

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2025
2025-05-13 English
8-K
Regulatory Filings
2025-05-13 English
FORM 4
Director's Dealing
2025-04-16 English
ARS
Annual Report
2025-04-09 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-09 English
FORM 3
Director's Dealing
2025-04-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.